High affinity mAb infusion can enhance maximum affinity maturation during HIV Env immunization.

Immune response Immunology Virology

Journal

iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038

Informations de publication

Date de publication:
19 Apr 2024
Historique:
received: 04 08 2023
revised: 27 11 2023
accepted: 09 03 2024
medline: 29 3 2024
pubmed: 29 3 2024
entrez: 29 3 2024
Statut: epublish

Résumé

Antigen-specific antibody infusion is known to enhance or suppress germinal center (GC) responses depending on the affinity of the infusion. We hypothesized that infusing monoclonal antibodies (mAbs) of escalating affinity during an immunization regimen may progressively escalate selection pressure on competing B cells, increasing their affinity. To test this, we immunized mice with HIV envelope gp120 and infused CD4 binding-site (CD4bs)-specific mAbs. While mAb infusion reduced somatic hypermutation (SHM) and affinity in most CD4bs-specific B cells, a sub-population was identified with greater SHM and affinity than control. High-throughput sequencing of plasma cells revealed that CD4bs-specific plasma cells possessed elevated SHM after mAb infusion, with phylogenetic tree topology that suggested more rapid differentiation. We therefore conclude, in accordance with other studies, that high-affinity mAb infusion primarily suppresses recruitment of most competing B cells but can increase and expedite affinity maturation of certain epitope-specific B cells.

Identifiants

pubmed: 38550978
doi: 10.1016/j.isci.2024.109495
pii: S2589-0042(24)00716-8
pmc: PMC10973984
doi:

Types de publication

Journal Article

Langues

eng

Pagination

109495

Informations de copyright

© 2024 The Authors.

Déclaration de conflit d'intérêts

R.P., J.P.A., D.H., A.B., W.T., T.W., and I.S.N. are employees and shareholders in GSK plc. No other authors have competing interests to declare.

Auteurs

Peter Thomas (P)

Institute of Immunity and Transplantation, Division of Infection and Immunity, University College London, London WC1E 6BT, UK.
Biopharmaceutical Molecular Discovery Group, GSK, Gunnels Wood Rd, Stevenage SG1 2NY, UK.

Chloe Rees-Spear (C)

Institute of Immunity and Transplantation, Division of Infection and Immunity, University College London, London WC1E 6BT, UK.

Sarah Griffith (S)

Institute of Immunity and Transplantation, Division of Infection and Immunity, University College London, London WC1E 6BT, UK.

Luke Muir (L)

Institute of Immunity and Transplantation, Division of Infection and Immunity, University College London, London WC1E 6BT, UK.

Emma Touizer (E)

Institute of Immunity and Transplantation, Division of Infection and Immunity, University College London, London WC1E 6BT, UK.

Raiees Andrabi (R)

Department of Medicine, University of Pennsylvania, Philadelphia 19104, PA, USA.

Richard Priest (R)

Biopharmaceutical Molecular Discovery Group, GSK, Gunnels Wood Rd, Stevenage SG1 2NY, UK.

Jennifer Percival-Alwyn (J)

Biopharmaceutical Molecular Discovery Group, GSK, Gunnels Wood Rd, Stevenage SG1 2NY, UK.

Darryl Hayward (D)

Biopharmaceutical Molecular Discovery Group, GSK, Gunnels Wood Rd, Stevenage SG1 2NY, UK.

Amanda Buxton (A)

In vivo Sciences and Delivery, GSK, Park Road, Ware SG12 0DP, UK.

William Traylen (W)

In vivo Sciences and Delivery, GSK, Park Road, Ware SG12 0DP, UK.

Benny Chain (B)

Institute of Immunity and Transplantation, Division of Infection and Immunity, University College London, London WC1E 6BT, UK.
Department of Computer Science, University College London, London WC1E 6EA, UK.

Trevor Wattam (T)

Biopharmaceutical Molecular Discovery Group, GSK, Gunnels Wood Rd, Stevenage SG1 2NY, UK.

Irene Sanjuan Nandin (IS)

Immunology Research Unit, GSK, Gunnels Wood Rd, Stevenage SG1 2NY, UK.

Laura E McCoy (LE)

Institute of Immunity and Transplantation, Division of Infection and Immunity, University College London, London WC1E 6BT, UK.

Classifications MeSH